Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1

被引：18

作者：

Oh, Dool-Ri ^{[1
,2
,3
]}

Kim, Jong Ro ^{[4
]}

Choi, Chul Yung ^{[3
]}

Choi, Chan-hun ^{[5
]}

Na, Chang-su ^{[5
]}

Kang, Bok Yun ^{[1
,2
]}

Kim, Seon-Jong ^{[5
,6
]}

Kim, Young Ran ^{[1
,2
]}

机构：

[1] Chonnam Natl Univ, Coll Pharm, Gwangju 61186, South Korea

[2] Chonnam Natl Univ, Res Inst Drug Dev, Gwangju 61186, South Korea

[3] Jeonnam Bioind Fdn, Jeollanamdo Inst Nat Resources Res JINR, Jeonnam 59338, South Korea

[4] MEGA BIO Co Ltd, Jeonnam 58141, South Korea

[5] Dongshin Univ, Coll Korean Med, 185 Geonjae Ro, Naju Si 58245, Jeollanam Do, South Korea

[6] Dongshin Univ, Dept Korean Med Rehabil, Mokpo Oriental Hosp, 313 Baengnyeon Daero, Mokpo 530822, South Korea

来源：

BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2019年 / 19卷 / 1期

关键词：

ChondroT; Hyperuricemia; URAT1; Uric acid; Xanthine oxidase; SERUM URIC-ACID; INHIBITOR; OSTEOARTHRITIS; ALLOPURINOL; PROGRESSION; FEBUXOSTAT; AGENT; LEVEL; RISK; WAN;

D O I：

10.1186/s12906-018-2415-2

中图分类号：

R [医药、卫生];

学科分类号：

10 ;

摘要：

BackgroundChondroT, a new herbal medication, consists of the water extracts of Osterici Radix, Lonicerae Folium, Angelicae Gigantis Radix, Clematidis Radix, and Phellodendri Cortex (6:4:4:4:3). We previously reported that ChondroT showed significant anti-arthritis and anti-inflammatory effects.MethodsThis study was designed to evaluate the effect of ChondroT on hyperuricemia. First, the effect of ChondroT was evaluated on xanthine oxidase (XOD) activity in vitro. The anti-hyperuricemic effect of ChondroT was also studied in potassium oxonate (PO)-induced hyperuricemic model mice. Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice. In addition, we measured serum creatinine (Cr) and blood urea nitrogen (BUN) levels as well as mRNA expression of the mouse urate transporter 1 (mURAT1) to evaluate kidney function and urate excretion in hyperuricemic mice.ResultsChondroT showed in vitro XOD inhibitory activity in a dose-dependent manner (P<0.05). We demonstrated that ChondroT (37.5, 75 and 150mg/kg) significantly reduced serum UA (P<0.01 and P<0.001, respectively), and upregulated urinary UA (P<0.001, respectively) in PO-induced hyperuricemic mice. In addition, ChondroT (75 and 150mg/kg) significantly reduced Cr (P<0.05 and P<0.01, respectively), BUN (P<0.05 and P<0.001, respectively), GOT (P<0.05 and P<0.01, respectively), and GPT (P>0.05 and P<0.05, respectively) levels in PO-induced hyperuricemic mice. ChondroT (75 and 150mg/kg) also significantly downregulated serum (P<0.05) and liver (P<0.05) XOD activity. Compared to the hyperuricemic mice, the ChondroT (37.5, 75, and 150mg/kg)-treated mice showed decreased mURAT1 protein expression level.ConclusionChondroT displayed anti-hyperuricemic effects by regulating XOD activity and kidney mURAT1.

引用

页数：8